AstraZeneca Pharma India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
AstraZeneca Pharma India reported strong full-year performance with total revenue from operations growing 33% to Rs 22,755.8 million (vs Rs 17,162.9 million in FY25). Profit after tax surged 62% to Rs 1,875.2 million from Rs 1,157.4 million, driven by Oncology segment revenue of Rs 16,100.9 million and Biopharmaceuticals at Rs 5,243.2 million. The company received 11 regulatory approvals including for Durvalumab, Eculizumab (rare disease), and Osimertinib. Exceptional items of Rs 52.5 million relate to closure of the Bangalore manufacturing site (operations ceased in Q2 FY25), while prior year included Rs 967.9 million in exceptional items including employee separation costs. The Board recommended dividend of Rs 36 per share (Rs 900 million total). Statutory auditors changed from Price Waterhouse & Co to BSR & Co. LLP from the 47th AGM.
Strong 33% revenue growth and 62% PAT growth indicate robust business momentum and successful execution of the specialty-focused strategy. The manufacturing site exit and clean audit opinion (unmodified) provide confidence in financial integrity.